ValuEngine downgraded shares of UCB (OTCMKTS:UCBJF) from a hold rating to a sell rating in a report issued on Saturday, ValuEngine reports.

Separately, Zacks Investment Research lowered Hersha Hospitality Trust from a buy rating to a hold rating in a research report on Thursday, May 2nd.

UCBJF traded down $2.47 on Friday, hitting $79.10. The company had a trading volume of 107 shares, compared to its average volume of 732. UCB has a 12-month low of $76.66 and a 12-month high of $94.30. The company’s fifty day moving average is $80.06.

UCB Company Profile

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

See Also: How to calculate compound interest

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with's FREE daily email newsletter.